THE FUTURE OF FOOD Disrupting protein production with microalgae
"By 2050, providing food for 10 billion people will become critical. Current protein sources cannot scale up without jeopardizing the environment.
French start-up Kyanos has developed a disruptive plant-based protein production te...
ver más
31/10/2019
Kyanos Biotech
71K€
Presupuesto del proyecto: 71K€
Líder del proyecto
KYANOS BIOTECHNOLOGIES
No se ha especificado una descripción o un objeto social para esta compañía.
Descripción del proyecto
"By 2050, providing food for 10 billion people will become critical. Current protein sources cannot scale up without jeopardizing the environment.
French start-up Kyanos has developed a disruptive plant-based protein production technology with no environmental downside. Its unlimited supply potential is in line with the food industry requirements.
With unprecedented yields, cost effectiveness and health safety conditions, this industrial process, called ""Cyclotrophy"" caters for the growing market expectations for healthy, environmentally-friendly products.
Cyclotrophy won the Most Novel Protein Process & IT award at the Protein Summit 2018. It boosts the production of microorganisms such as microalgae and eliminates the unpredictability and the contaminants that affect traditional microalgae production. The process relies on smarter, more compact and more efficient production infrastructure and takes 20 times less space for a similar output. A fully functional lab-scale pilot is already running using AFA microalgae (Aphanizomenon flos-aquae). Thanks to a partnership with Altran Group, Kyanos is now about to ramp-up to the industrial scale.
The production capacity of the first factory is devised to quickly grow to reach 100 tonnes of AFA microalgae per year by 2023.
Kyanos will first target the high-margin dietary supplements market before addressing the massive food-ingredients demand. Drawing on existing distribution channels and health prescription dynamics, the initial product, AFA microalgae powder, will be sold to global health supplements companies. Kyanos will initiate EU distribution from year 2 onwards. In 2023, exports throughout Europe will represent 95% of the production, presumably gaining a 10% market share and inducing up to 110 indirect job creations in France and Europe
The objectives of the SMEi1 are: to secure full-scale design for the Cyclotrophy process scale-up; IP, FTO analysis and global market survey to schedule commercialization actions."
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.